Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138734 | Leukemia Research | 2010 | 5 Pages |
Abstract
The monoclonal antibody Rituximab is useful for treatment of patients with B-cell non-Hodgkin's lymphoma. We phenotypically analyzed reconstitution of peripheral B cells in a male patient with follicular lymphoma following their depletion with Rituximab. CD19+ and CD20+ B cell counts in peripheral blood decreased rapidly following Rituximab treatment. Six months after the end of treatment, a few CD19+ B cells were detected in peripheral blood. These cells had a naive B cell phenotype (IgD+, CD27−) and they expressed high levels of CD38 and CD24, which show that the B cell pool was repopulated mainly with immature, naive B cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Abdulmunem M. Abulayha, Salah A. Tabal, Eman I. Shawesh, Mohamed A. Elbasir, Abdulrhman S. Elbanani, Yosra M. Lamami, Amin Bredan,